RNS Number : 5295Z
Avacta Group PLC
08 April 2026
Avacta Announces 2026 Science Day Event
LONDON and PHILADELPHIA - April 8, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to extend an open invitation for colleagues and investors to attend the Company's 2026 Science Day: "The Next Chapter of pre|CISION."
The Avacta Science Day event for investors will take place in Central London on May 6, 2026 commencing at 10.30 AM, at the Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA. Avacta team members will share presentations on the company's scientific achievements and our aspirations, to be followed by a reception for attendees.
Attendance will be limited by the capacity of the venue, so attendees will be accepted on a first come, first served basis. Investors wishing to attend should please indicate interest by email at investors@avacta.com.
For investors unable to attend in person, the event will be professionally recorded and the video made available on the Avacta website in due course.
-Ends-
For further information from Avacta, please contact:
Avacta Group plc Christina Coughlin, Chief Executive Officer
https://avacta.com/ via Cohesion Bureau
Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance
www.strandhanson.co.uk
Zeus (Broker) James Hornigold / George Duxberry / Dominic King
www.zeuscapital.co.uk
Cohesion Bureau Communications / Media / Investors Richard Jarvis
avacta@cohesionbureau.com
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.
Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma.
About FAP-Exd (AVA6103)
AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Gen Two innovative pre|CISION® sustained release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAEAKLXEDFKEFA
